Compare Ishares Msci Thailand Etf (THD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Thailand Etf vs Tango Therapeutics Inc. — how do they compare? Ishares Msci Thailand Etf trades at $71.15 (market cap $424.09M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 8.8× Ishares Msci Thailand Etf's market cap, and Ishares Msci Thailand Etf is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Thailand Etf for 67 Days and Tango Therapeutics Inc. for 0 Days on average.
| THD | TNGX | |
|---|---|---|
Market Cap | $424.09M | $3.75B |
Volume | 1,217,048 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $75.06 | $32.90 |
52-Week Low | $57.86 | $7.50 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
THD (iShares MSCI Thailand ETF) trades at $71.17, down 0.27% with bearish technical signals across moving averages and oscillators. Short interest surged 90.6% in September 2026 (Defense World, 2026-10-01), indicating rising bearish sentiment. The ETF has delivered strong 38% returns over the past year (Seeking Alpha, 2026-07-09) but faces headwinds from capital rotation away from Asian AI-related markets.
Outlook remains cautious given technical weakness and elevated short positioning. Investment opportunity exists for exposure to Thailand's AI hardware plays like Delta Electronics, but vulnerability to profit-taking and regional capital outflows presents significant near-term risks for shareholders.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
